Greater access to IPOs through OnMarket BookBuilds

State One has partnered with OnMarket BookBuilds to provide our clients with even more investment opportunities. In addition to the exclusive capital raisings that State One undertakes and offers to our clients, you can now take advantage of offers from OnMarket. Our association with OnMarket will allow you to bid directly on IPOs and have the shares allocated straight to your holdings at State One. Through OnMarket our clients will also be able to access free research, management interviews and get notifications on upcoming IPOs.

OnMarket is Australia’s first online platform that lets all investors buy shares in IPOs free of any fees other than the cost of the shares. Since launching in October 2015 OnMarket has hosted 1 in 3 ASX IPOs, so we are obviously excited to be able to offer our clients access to this cutting-edge platform. For each offer hosted by OnMarket you get easy bidding & payment, free independent research, and a chance to 'meet the management' via exclusive video interviews. Best of all, when you invest in IPOs via OnMarket, any shares you buy can be allocated directly to your State One Stockbroking account so you can manage your portfolio without disruption.

How does it work?

We will display the list of current offers from OnMarket on our website. If you see an offer that you want to invest in then click on the Bid Now button to apply for shares. You will leave State One website and be redirected to our partner's (OnMarket) bidding platform where you will need to sign up with your Holder Identification Number (HIN). If you have already signed up then you will be taken straight to the bidding page for the selected offer.

It is important that you enter your HIN correctly when you set up your login at OnMarket. This will make for a seamless experience if you want your shares to be automatically allocated to your State One account.

Current OnMarket Offers

IPO
Biotech
$0.20
Size of Offer Up to A$7 million
Minimum Bid $2,000.00
Opening Date 25/02/2019
Closing Date 22/03/2019

Introduction

Koligo Therapeutics Ltd (ASX: KOL) (the Company) was incorporated on 27 June 2018 for the primary purpose of acquiring Koligo Therapeutics, Inc (Koligo) a US biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.

Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, for the treatment of chronic pancreatitis patients, in the United States.  Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Since 14 months ago, when sales commenced to a limited number of initial hospital customers, Koligo has generated revenues of approximately $1,600,000 from sales of this product.  

Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend the product’s shelf life and thus expand Koligo’s geographic reach. Koligo also seeks to develop and commercialize a range of other transformative cell therapies for a range of indications, including type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders. Oversimplifying somewhat, pre-vascularised cell/tissue structures are 3D bio-printed for transplantation into humans with blood vessels already embedded in the tissue.

 

Koligo’s short to medium-term Product Pipeline

Koligo’s longer-term Project Pipeline

Koligo’s proprietary cell therapy, 3D bioprinting, and tissue engineering technologies are protected by patents exclusively licensed by Koligo, a patent application filed by Koligo, and non-patented proprietary databases, processes, and know-how owned by Koligo.

Investment Highlights

  • Commenced sales of cell therapy product Kyslecel™ for the treatment of chronic or acute recurrent pancreatitis, already generating over $1,600,000 in revenue
  • Significant unmet medical need for Kyslecel™, as the current treatments for chronic or acute recurrent pancreatitis seldom provide meaningful long-term relief to patients
  • No other business or enterprise is known by Koligo to be widely selling a product similar to Kyslecel™ as a commercial for-profit endeavour
  • India and China are among the countries with large numbers of pancreatitis sufferers, and Koligo is planning to enter international markets, potentially through out-licensing and partnerships with established market participants, subject to the receipt of all relevant regulatory approvals
  • The pre-clinical pipeline includes novel engineered tissue products containing pancreatic islets for the treatment of pancreatitis, type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders
  • Potential to become a successful regenerative medicine platform for the development and commercialisation of scalable bioengineered tissue transplant products
  • Backed by US based institutional investor who also previously backed the ASX-listed Keytone Dairy and DroneShield
  • Board and management with significant experience in regenerative medicine, biotech and successful ASX-listed small-cap companies (including Immutep (formerly Prima BioMed), nearmap and iiNet
  • Australian public markets are home to several regenerative medicine companies, including Cynata Therapeutics (ASX:CYP), Polynovo (ASX:PNV), and most recently, Exopharm (ASX:EX1) listed in December 2018. On listing, the only 3D bioprinting company on the ASX

Offer overview

The Company is raising $6 million with the ability to accept oversubscriptions of an additional $1 million, for a total of $7 million.  

The proceeds of the offer will be used for the following:

  • Research and development;
  • Expansion of sales and operational staff
  • Expansion of manufacturing facilities;
  • Working capital; and
  • Costs associated with the listing and the IPO.

Koligo’s Products in More Detail

Kyslecel™

Chronic or acute recurrent pancreatitis is a painful, long-standing inflammation of the pancreas that alters the organ’s normal structure, gets worse over time and leads to permanent damage. The disease eventually impairs a patient’s ability to digest food and make pancreatic hormones which are critical to controlling energy levels in the blood. Chronic or acute recurrent pancreatitis has increased worldwide due to better diagnosis, increasing obesity, and increasing alcohol consumption in the developed world.  In the U.S., chronic or acute recurrent pancreatitis affects approximately 128,000 people, with an estimated 16,000 to 39,000 new diagnoses each year.

 

There are several medical treatments available for the treatment of chronic or acute recurrent pancreatitis. One such treatment undertaken by patients is a Total Pancreatectomy (“TP”), which involves the surgical removal of a patient’s entire pancreas. TP is effective at reducing pain in 85-94% of patients; however, it immediately results in type 3c diabetes due to removal of the regions of the pancreas (islets) that produce insulin.

Kyslecel™ is used after a patient has undergone a TP to relieve the pain and inflammation caused by chronic or acute recurrent pancreatitis. Kyslecel™ is an islet-autotransplantation (IAT) product, i.e., a product made from a patient’s own pancreatic islets (the cells that produce insulin) that are reintroduced into a patient’s body to produce insulin needed to regulate blood sugar. TP results in immediate diabetes for the patient, and Kyslecel™ can reduce the risk of diabetes from TP by preserving the patient’s insulin-producing cells (pancreatic islets) that regulate blood sugar. Below is a summary of the process involved in TP-IAT involving Kyslecel™.

Without access to TP with Kyslecel™, patients generally have limited treatment options (such as therapeutic endoscopy, partial pancreatic resections, and pain management with powerful opioids) that provide limited relief.

 

The diagram above shows how Kyslecel is used.

Kyslecel™v2.0

Koligo is currently developing Kyslecel™ v2.0, an improved formulation of Kyslecel™ that is intended to extend its shelf life. Kyslecel™ v2.0 is expected to launch in the second half of 2019, subject to completion of its development, and will allow Koligo to ship Kyslecel™ over longer distances, including international markets.

Other Products

Koligo also intends to develop and commercialise a pipeline of regenerative medicine products that will utilise 3D bioprinting, adipose-derived cells (regenerative cells derived from fat tissue) and other tissue processing techniques (referred to as Koligo’s 3D-V technology platform) for novel cell therapy and engineered tissue products. The initial additional products that Koligo intends to develop using its 3D-V technology platform are KT-CP-203 and KT-DM-103 (Stylecel-L), engineered tissue products containing pancreatic islets for the treatment of pancreatitis, type 1 diabetes, and other pancreatic diseases.

Longer term, the Company aims to be a leader in the development of novel cell therapy and engineered tissue products for liver failure, neurological diseases, metabolic disorders, and genetic disorders, using Koligo’s 3D-V technology platform.

Images (clockwise from top L to R): Spheriods being bio-printed, islets that have re-vascularised, magnified images of bio-printed spheroid containing islets.

Revenue Model

Koligo’s revenue is derived principally from the sale of products and performance of services to hospitals. Revenue is earned and recognised when product and services are received by the customer.

Growth Strategy

In order to increase its sales of Kyslecel™ (and subsequently Kyslecel™ v2.0), Koligo intends to focus on the following growth strategies:

  • expanding Koligo’s sales force and investing in the marketing of Kyslecel™;
  • increasing the number of insurers that reimburse for Kyslecel™;
  • expanding the network of hospitals and doctors who offer Kyslecel™; and
  • evaluating international opportunities for Kyslecel™ v2.0 through potential licensing and collaboration agreements for specific countries and regions.

Beyond increasing the sales of these products, Koligo is seeking to develop and commercialise a range of other products for a range of indications, as described above.

Board and Management

Members of the Company’s Board and management are experienced in the regenerative medicine industry and in successful ASX small-caps. The calibre, ability and relevant experience of the Board are highlighted by the following:

  • Matthew Lehman Executive Director and Chief Executive Officer has over 18 years’ executive experience at numerous biotechnology and pharmaceutical companies, including Immutep (ASX:IMM; NASDAQ:IMPP) (formerly Prima BioMed (ASX:PRR; NASDAQ:PBMD);
  • Peter James, Non-Executive Chairman has over 30 years’ public company experience as Chair, Non-Executive Director and Chief Executive Officer across a range of publicly listed and private companies. He is currently Chair of several ASX-listed companies, including Macquarie Telecom, nearmap Ltd, DroneShield and Keytone Dairy Corporation;
  • Stuart Williams PhD, Executive Director and Chief Technology Officer is an internationally recognised expert in regenerative medicine and is the Endowed Chair of Cardiovascular Innovation and Director of the Bioficial Organs Program at the University of Louisville;
  • Balamurugan Appakalai, PhD (Chief of Manufacturing) is a well-recognized pioneer in islet isolation technology and has processed 800+ human pancreases; and
  • Mike Hughes, MD (Chief Medical Officer) started the clinical islet transplant program at the Jewish Hospital in Louisville, Kentucky.

Risks

You are encouraged to read the Replacement Prospectus carefully as it contains detailed information about the Company and the Offer. Like all investments, an investment in the Company carries risk. As set out in Section 7 of the replacement prospectus, the Company is subject to a range of risks, including but not limited including regulatory risks, market adoption and ongoing acceptance of Kyslecel™, intellectual property protection, product development for the pipeline and manufacturing and facilities risks.

 

Section 734(6) disclosure: The issuer of the securities is Koligo Therapeutics Limited ACN 627 117 677. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. 

OnMarket has a limited allocation. The offer may close early and the 'Pay By' dates may change. Duplicate bids under the same investment profile, investor name or residential address may be cancelled.

The information contained herein is intended solely for persons within Australia. This communication is not for publication or distribution, directly or indirectly, in or into the United States of America, including its territories and possessions, any state of the United States of America and the District of Colombia (collectively, the “US”). This communication is not an offer of securities for sale into the US. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the US, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the US.

IPO
Software & Services
$0.25
Size of Offer Up to A$3.5 million
Minimum Bid $2,000.00
Opening Date 11/10/2018
Closing Date 8/03/2019

 

Offer closed via OnMarket. 

Update

AXS Group Ltd have released an Investor Update covering three key updates to the offer:

  • forecast revenues of $5.1 million for FY2019 and $7.5 million for FY2020. Strong growth from FY2018 revenue of $3.2 million
  • 30 June 2018 financial information
  • an update its material contracts including the deployment with IA Financial Group’s 25,000 brokers network. IA Group is a C$6 billion life and health insurance company in Canada.  The new software license and price structure allowing growth in revenue to match growth in customer transactions and funds under management.

Based on the above FY2020 revenue forecast, this equates to EV/Revenue of 3.07x on max IPO raise of $3.5M. On forecast revenue we expect EBIT of at least $2M.

Read the the Investor Update here

Introduction

AXS Group Limited (ASX Code: AXS) is a global software provider of hosted, SaaS and cloud-based solutions to clients in the financial services and operates an end-to-end process architecture for clients in the wealth management sector.  The company has a track record of successfully tendering and integrating businesses into its ARMnet software with approximately over 75 third party systems integrations performed for clients with varying customised solutions found. The ARMnet platform uses cognitive processes, including robotic process automation and blockchain techniques to give real time output, reducing time and cutting costs.

AXS provides its clients with a digital transformation through its internally owned and developed software platform, ARMnet. The ARMnet platform is a customer relationship management (CRM) financial product management solution that is built on an industry standard Microsoft dot.net framework. It enables clients to improve business efficiency, productivity and accountability, while lowering the costs and risks in delivering different kinds of financial services solutions. 

On completion of the IPO, AXS Group will complete the acquisition of Axcess Consulting Group Pty Ltd the operating entity, which is a global integrated software solution provider to the finance, insurance and funds sectors and has grown organically and operated for over 13 years.

Offer overview

AXS Group Limited is looking to raise up to $3.5 million with an option to accept another $500,000 in oversubscriptions and will have an indicative market capitalisation of approximately $25.0 million at maximum subscription.

The proceeds of the offer will be used to:

  • expand the Group’s executive, sales and marketing teams;
  • provide Working capital; and
  • cover the costs of the offer

AXS client base

AXS provides clients software services for varying business sectors including a strong position in the non-bank software lending market. These clients are geographically spread across North America, Europe and Asia-Pacific region. The business is characterised by strong recurring revenue and high levels of client retention, being approximately 90% since inception. The ARMnet platform is currently used to manage over $100 billion of assets and transactions for clients worldwide.

Key Clients:

Revenue Model

AXS Group Limited revenues are generated by subscription and licensing, maintenance, personalisation and servicing fees, typically charged in accordance with agreed rates set out in service agreements with each respective client. Subscription and licencing revenues are recurring annuity revenue streams that contribute approximately 50% to total revenue.

The table below provides an overview of the types of fees charged by AXS.

Product Modules

Technological advances continue to develop in the back office which now offers the financial services industry the ability to do things more efficiently and cost effectively. The Company is to be a key driver in this market and from its ARMnet technology platform, operates two business lines: Platform Product Solutions and Service Solutions. The platform uses cognitive processes, including robotic process, automation and blockchain techniques to give real time output, reducing time and cutting costs.

AXS product offering is divided into 7 product modules on a subscription basis and 3 user services modules on the ARMnet platform. More modules will be introduced upon identification of further market opportunities with each based on pricing.

Industry Overview

The AXS Group currently focuses on providing its software platform solution to the wealth management industry, which involves businesses that provide investment services and financial advice, with the objective of supporting clients to grow their individual wealth. This includes business processing centres, mortgage providers, trustees, asset managers, family offices, private investor groups, public offer funds, and self-managed superannuation funds (SMSFs). As of June 2016, there were approximately 8,200 active businesses in Australia involved in financial asset investing, and approximately 4,000 superannuation funds (excluding SMSFs). There are almost 600,000 SMSFs, 1,500 charitable trusts that manage investments and over 25,000 active financial advisers.

AXS can be viewed as a provider of disruptive technology in the financial services sector, in which large companies, such as Fiserve and FIS Global, have traditionally dominated. Globally, total Information Technology (“IT”) expenditure is projected to total US$3.7 trillion in 2018, an increase of 4.5% from 2017. Corporate business software use continues to exhibit strong growth, with worldwide software spending projected to grow 9.5% in 2018, and it will grow another 8.4% in 2019 to total US$421 billion.1 Organisations are expected to increase spending on software in 2018, with more of the budget shifting to software as a service (“SaaS”).

Growth Strategy

AXS Group’s growth strategies include:

  • Organic expansion. The Group intends to grow the use of the ARMnet platform and its product and service lines through increased marketing and promotion and the education of existing or new customers by its sales managers.
  • Cross selling of products and services. The ability to acquire companies with leading software capabilities provides the group with the opportunity to cross sell software products across their expanded customer base.
  • Ongoing growth in funds management. Revenues can in some cases be linked to the size and volume of its clients’ underlying funds . In the event that AXS extends the nature of funds administration services beyond that currently offered, it will consider acquiring an AFSL to enable a further widening of its product administration offering.
  • Ongoing growth in superannuation in Australia. The Group believes it can leverage its ARMnet software expertise for super administration.
  • Expansion of operational footprint through acquisition. To accelerate the execution of the Group’s strategy and growth, the Group may make strategic acquisitions of specific software providers or other synergistic businesses.
  • Group business across the broader Asia Pacific, Canada and United States region. AXS will continue to broaden its service offering software solutions into third party administration and business processing centres. This shall include expansion, both domestically and offshore into Europe, Asia and North America.

Board and Management

The AXS Group is led by a well-credentialed and balanced Board and management team with experience in the financial services, information technology and software development industries. This includes:

  • Nick Brookes (Non-Executive Chairman), founder of CCSL Ltd and until recently was the Chairman of Linear Asset Management Ltd.
  • David Grey, Managing Director and CEO -  has over 30 years management, corporate and financial services experience and previously worked with Texas Instruments, AWA Limited, National Benefits Consulting, AM Corporation Ltd, Millinium Capital Group, AMP Superannuation Ltd, CUSCAL, Perpetual Trustees Australia Ltd and Australian Wealth Management Limited.
  • Ivan Colak, Executive Director - co-founder and director of Axcess Consulting with more than 30 years of domestic and global experience in technology services.
  • Andrew Duncan, Chief Financial Officer - is a Chartered Accountant with over 20 years’ experience specialising in forensic accounting, transaction services and was accepted by the Institute of Chartered Accountants as a Business Valuation Specialist. 

Risks

You are encouraged to read the Prospectus carefully as it contains detailed information about the Company and the Offer. Like all investments, an investment in the Company carries risk. As set out in Section 8 of the Prospectus, AXS Group Limited is subject to a range of risks, including but not limited to reliance on key personnel, risk of significant control by Existing Shareholders, replicability of business model or failure to retain existing clients and attract new clients.

 

Section 734(6) disclosure: The issuer of the securities is AXS Group Limited ACN 619 705 207. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above).​

OnMarket has a limited allocation. The offer may close early and the 'Pay By' dates may change. Bids over $10,000 may be scaled back more heavily. Duplicate bids under the same investment profile, investor name or residential address may be cancelled.

IPO
Food & Beverage
$0.20
Size of Offer Up to A$8 million
Minimum Bid $2,000.00
Opening Date 12/03/2019
Closing Date 22/03/2019

 

The Australian Nutrition & Sports Ltd IPO has closed early via OnMarket.  Payments for applications are now due by 5pm, Friday 22 March (AEDT).

Introduction

Australian Nutrition & Sports Ltd (ASX: AN1) is an Australian based company, committed to developing, sourcing and marketing high quality Australian made milk formula and nutrition and wellness products for sale in China, Hong Kong and Australia. In the future they plan to expand into other Asian markets.

Currently focused on infant and adult milk formula products, protein based health and wellness nutritional products, ANS’s business model is to develop and brand its own high-quality products, and then to develop distribution channels for the profitable sale of the products. In doing this ANS currently intends to rely on a capital light business model by outsourcing the production of its products to various export accredited Australian third-party producers.

All of ANS’s nutrition and milk formula products are made in Australia at export quality and with all required export certifications. These certifications include the coveted China Certification and Accreditation Administration (CNCA) for the milk formula products. A number of the protein supplements are also approved by China Inspection and Quarantine (CIQ) for the import and sale of products in China.

The market segments in which ANS participates are both growing markets, with health and wellness being a growing industry, particularly in Asia. With the removal of the one child policy in the PRC, and the growing population and growing affluence of the population in Asia in general, ANS believes that the demand for premium nutrition and milk formula products from Australia will continue to grow.

ANS has successfully commercialised a number of products in the Hong Kong market with distributions agreements in places with leading pharmacy groups including Watsons and Mannings. In FY2018, ANS generated cash sales of $419,260, up 192% from FY2017 sales of $218,033.

 

Investment Highlights

  • Premium quality, health and nutrition products sourced and produced in Australia
  • Two complementary product categories, with a total of 23 nutrition products and 4 milk formula products
  • Targeting growing Chinese and South East Asian markets with increased focus on health and wellbeing
  • Third party agreements with accredited manufacturers that hold required accreditations and licences for import and sale of products into China (CNCA and CIQ approved)
  • Executed Agreements for the distribution of products with Watsons and Mannings, Hong Kong’s two largest chain of chemists
  • Commencing Infant Milk Powder sales into mainland China via domestic Chinese e-commerce channels such as KKSKY (www.kksky.com) and Jing Dong (www.JD.com)
  • Generated cash sales of $419k in FY2018, up 192% of FY2017 sales.
  • Board and management with significant experience in global distribution networks sales and marketing in Asia

    Offer Overview

    Australian Nutrition & Sports Limited is looking to raise up to $8 million via its IPO and will have an indicative market capitalisation of approximately $19.1 million at maximum subscription.  

    The proceeds of the IPO will be used to:

    • increase the sales and marketing budget to expand brand awareness to drive both direct and retail channel sales for ANS’s current commercialised products with a focus on export markets;
    • grow sales and brand presence in Hong Kong by continuing to add new customers to the network with a secondary focus to expand in other Asian markets in which the company already has a presence;
    • rebrand the nutrition and fitness product ranges;
    • invest upstream into IMF and protein manufacturers;
    • continue the commercialisation of the portfolio of product formulations;
    • Provide working capital; and
    • cover costs associated with an ASX-listed company, and other typical administration costs.

    Business Model

    Australian Nutrition & Sports Ltd’s business model is to develop and brand its own high-quality products for the market segments in which it operates, and then to develop distribution channels for the profitable sale of the products. In doing this the company currently intends to rely on a capital light business model by outsourcing the production of its products to various third-party producers.

    All of the company’s nutrition and milk formula products are made in Australia at export quality and with all required export certifications. Outsourcing the production of its products to third parties gives the company the advantage of requiring less capital intensity, and also de-risks the supply of products as it reduces the risk to the company that would be caused by the loss of regulatory accreditation of, or other manufacturing disruption at, a company owned production facility.

    ANS Australia executed a supply agreement with Nature One Dairy in October 2018 for the manufacture and supply of Infant and Adult products. As part of the agreement, NOD agrees to supply IMF and AMF products to ANS Australia from its CNCA approved facility in Melbourne.

    Products

    Australian Nutrition & Sports Ltd has a broad and diverse product range comprising two main product classes, being milk formula and nutrition products:

    Milk Formula

    Australian Nutrition and Sports Ltd offers a range of milk formula products with four commercialised products. Three of the products are developed specifically to address the different stages of infant growth as a nutritional alternative to breast milk for growing infants. All milk formula products meet stringent export regulations and are Australian made in National Association of Testing Authorities (NATA) accredited laboratories.

    Nutrition

    In addition to the extensive milk formula range, the company has a range of Australian-made, export quality nutrition products with all required certifications, including protein powders, protein shakes, protein bars and rapid energy gels.

     

    Business Strategy

    Execution of the brand marketing strategy "The ANSWER".

    The company will focus its initial marketing efforts on promoting its brand and increasing awareness of our existing product range, with a view to increasing sales through existing distributors and retailers, as well as growing its network of distributors and retailers in Australia and abroad.

    Continue China expansion

    The distribution of IMF and AMF products into China is undertaken currently via CBEC (Cross Border e-Commerce) sales channel. This sales channel is large, is expected to continue to grow and is the current primary sales channel that the company will focus on for the sale of its IMF and AMF products into China. The company additionally intends to explore opportunities to sell its AMF products offline through traditional retail channels in China.

    Improve Australian market presence

    The company’s nutrition and protein products are currently sold in Australia in gym and fitness centres with its IMF and AMF products sold in a small number of retail outlets. The company intends to undertake an expansion of its IMF and AMF products into retail stores Australia-wide

    Industry Overview

    In September 2016, the nutrition, health and wellness industry had an estimated global market size of US$570 billion. Key demand factors that have been observed by the company in the market are: population growth; growth in the middle classes (particularly in China); positive social trends regarding health and wellness; and governments willingness to implement initiatives to address public health and ageing populations. The key component of the company’s PBNM products is Australian sourced protein, which is ultimately sourced from cow milk.

    Australia has abundant pasture and other resources for production of dairy based products, making it well positioned to meet China’s growing demand for dairy and nutrition products.

    Management and Board

    Australian Nutrition & Sports Ltd is led by a highly experienced Board with skills in supply chain management, global distribution networks, sales and marketing in Asia.

    • Thomas Lashan - Managing Director and CEO, with more than 20 years experience in the health, wellness and fitness industry in Australia and China. In 2006, he founded the company based on insights gained in his lengthy career as a leading Personal Trainer and Life Coach in Melbourne. Mr Lashan personally led the expansion into Hong Kong and CHina.
    • Peter Reilly - Non-Executive Chairman, with more than 30 years’ experience as a senior executive with public and private companies, including being the managing director of Ausdoc Group Pty Ltd.
    • Alexander Molyneux - Non-Executive Director with more than 10 years’ experience as a financier and company director.  Mr Molyneux is currently Non-Executive Chairman of Argosy Minerals Ltd (ASX:AGY), Chairman of Tempus Resources Ltd (ASX:TMR), and Managing Director of Galena Mining Ltd (ASX:G1A).
    • Simon Fraser - Non-Executive Director, held executive positions with various FMCG organisations over the past 25+ years. This includes Proctor and Gamble where he has held several senior executive positions in Australia and in Asia over a 20-year career.

    Risks

    You are encouraged to read the Prospectus carefully as it contains detailed information about the Company and the Offer. Like all investments, an investment in the Company carries risk. As set out in Section 4 of the Prospectus, Australian Nutrition & Sports Limited is subject to a range of risks, including but not limited to business strategy and execution risk, limited history in the nutritional health and food products market, dependence on service providers and risks in ability to export food products to Asian markets.

     

    Section 734(6) disclosure: The issuer of the securities is Australian Nutrition & Sports Limited ACN 625 485 912. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. 

    OnMarket has a limited allocation. The offer may close early and the 'Pay By' dates may change. Bids over $10,000 may be scaled back more heavily. Duplicate bids under the same investment profile, investor name or residential address may be cancelled.

    Disclaimer: All information on this section is of a general nature. Before making any investment decision, please seek the relevant advice.

    Back to top